Invirsa
INV-102 is a novel eye drop that promotes accelerated healing through DNA repair. INV-102 is the first drug to show promise in treating ocular sulfur mustard injury, and therefore, Invirsa is the first ophthalmic therapeutic company to sign a contract with BARDA to develop a medical countermeasure. BARDA is funding INV-102’s commercial indication clinical trials so that INV-102 is available nationwide in case of a sulfur mustard event.